Institute Of Hematology & Blood Diseases Hospital, China

This study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The goal was to see if these regimens could safely raise platelet counts and reduce bleeding. The approac…

This study tested a new treatment for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment combined three drugs: rabbit antithymocyte globulin, cyclosporine, and levamisole. The goal was to see if this combinati…

This study tested a drug called lusutrombopag in 17 Chinese adults with persistent or chronic immune thrombocytopenia (ITP) who had not responded to standard treatments. The goal was to see if the drug could safely raise their platelet counts to safer levels. Participants took th…

This study tested a drug called eltrombopag in 48 adults with chronic hepatitis B who also had a low platelet count (immune thrombocytopenia). The goal was to see if taking the drug for 6 weeks could safely raise platelet levels to reduce bleeding risk. Results focused on how man…

This study tested a combination of two drugs, bortezomib and dexamethasone, in 18 adults with acquired pure red cell aplasia (a rare condition where the body stops making red blood cells) whose first treatment didn't work or stopped working. The goal was to see if this combo coul…

This study tested a two-part chemotherapy plan (EDOCH and DHAP) with or without the targeted drug rituximab for people 65 and younger newly diagnosed with mantle cell lymphoma. The goal was to see how well the treatment controlled the disease and whether adding rituximab helped. …

This study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination works better at controlling the disease and improving survival without progression. Participants received …

This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The main goal was to check sa…

This early study tested a new stem cell treatment called ET-01 in 3 people with transfusion-dependent beta-thalassemia, a serious blood disorder that requires regular blood transfusions. The treatment uses the patient's own stem cells, which are modified and then given back to he…

This early-stage study tested a new treatment called C-CAR066 in 7 adults with diffuse large B-cell lymphoma whose cancer returned or didn't respond after a prior CAR-T therapy. The treatment uses a patient's own immune cells, modified to target the CD20 protein on cancer cells. …

This study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission without …

This study tested two treatments for acquired hemophilia A, a rare condition where the immune system attacks clotting factors, causing severe bleeding. 66 adults received either steroids with cyclophosphamide or steroids with rituximab. The goal was to see which combination bette…

This study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a fast-growing leukemia (Ph+ ALL). The goal was to see if the combination helps people live longer and keeps the cancer away. Participants took dasatinib daily for up t…

This early-phase study tested a new treatment called BZ019 in 12 adults with certain types of B-cell lymphoma that had stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and…

This study tested a treatment using specially engineered immune cells (CD19 CAR T cells) in 20 adults with a type of blood cancer called B-cell lymphoma that had come back or not responded to standard therapy. The cells were given in three doses over three days. The goal was to s…

This study looked at whether a stem cell transplant (using a patient's own cells) could help people with a high-risk form of Waldenström macroglobulinemia live longer compared to standard chemotherapy. About 70 adults aged 18 to 70 with this rare blood cancer took part. The main …

This study tested a three-drug oral regimen (thalidomide, cyclophosphamide, and dexamethasone) followed by maintenance therapy (thalidomide and prednisone) in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the treat…

This early-phase study tested a new therapy made from lab-grown natural killer (NK) cells in 2 adults with acute myeloid leukemia (AML) that had come back or was hard to treat. The goal was to see if the treatment is safe and to get a first look at whether it can reduce signs of …

This early-phase study tested a new cell therapy called LILRB4 STAR-T cells in one person with monocytic leukemia (a type of blood cancer). The goal was to see if the treatment is safe and can reduce cancer in the bone marrow. Researchers monitored side effects like immune reacti…

This study looked at whether the drug posaconazole can prevent lung fungal infections in 360 people who had a stem cell transplant. Researchers measured drug levels in the blood and checked for side effects. The goal was to find the right dose to keep patients safe from serious i…

This study looked at 60 blood cancer patients who had a stem cell transplant and later developed a serious fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) and during the pandemic (2020-2024) to see how the virus, new tests, and treatme…

This study looked back at 320 children with acute myeloid leukemia (AML) to compare two different chemotherapy treatment plans. The goal was to see if a newer plan (CAMS-2009) helped children live longer or stay cancer-free better than the older plan (CAMS-2005). The researchers …